ReviewEye (London, England)2024
MOG antibody-associated optic neuritis.
Review in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Identification of risk factors for relapse at initial onset in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis using ophthalmic findings.Japanese journal of ophthalmology · 2026Article
- OCT-defined optic atrophy thresholds are associated with blunted optic nerve swelling in recurrent optic neuritis.Multiple sclerosis and related disorders · 2026Article
- Clinical risk factors for recurrence in adult-onset myelin oligodendrocyte glycoprotein antibody-associated optic neuritis.BMC ophthalmology · 2026Article
- Atypical retrobulbar optic neuropathy after semaglutide escalation.JCEM case reports · 2026Article
- MOGAD update: new phenotypes in the expanding clinical spectrum.Journal of neurology · 2026Review
- Functional and structural outcomes in paediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a prospective study.Documenta ophthalmologica. Advances in ophthalmology · 2026Article
- Lymphomatosis Cerebri Presenting as Steroid-Refractory Demyelinating Disease: A Diagnostic Challenge.Cureus · 2026Article
- Overlapping autoimmunity and demyelination syndromes associated with TNF inhibitor therapy.Clinical rheumatology · 2026Review
- Bilateral myelin oligodendrocyte glycoprotein antibody-associated disease after cataract surgery.American journal of ophthalmology case reports · 2026Article
- OCT-Based Differentiation of First Acute Optic Neuritis: An International Study of 111 Patients With NMOSD and MOGAD.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- 후뇌염의 영상 소견 스펙트럼: 임상 화보.Journal of the Korean Society of Radiology · 2026Review
- Coexistence of MOG-IgG-associated bilateral optic neuritis with psoriasis vulgaris and psoriatic arthritis in an Asian patient: a rare case report.BMC ophthalmology · 2026Article
- A rare presentation of pediatric MOG-antibody-associated neuroretinitis: a case report.BMC neurology · 2026Article
- Bilateral Optic Neuritis as the Initial Presentation of Acute HIV Infection in a Young Bodybuilder: A Case Report.Reports (MDPI) · 2026Article
- From the Optic Neuritis Treatment Trial to Antibody-Mediated Optic Neuritis: Four Decades of Progress and Unanswered Questions.Biomedicines · 2026Review
- A Case Report of Rare MOG Antibody-Associated Optic Neuritis Related to Hepatitis E Virus Infection.Infection and drug resistance · 2026Article
- Clinical Features and Management of Optic Neuritis in a Cohort of Patients with Combined Central and Peripheral Demyelination.Neuro-ophthalmology (Aeolus Press) · 2026Article
- Significance of brain lesions associated with optic neuritis in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.Multiple sclerosis and related disorders · 2025Article
- Live Cell-Based Semi-Quantitative Stratification Highlights Titre-Dependent Phenotypic Heterogeneity in MOGAD: A Single-Centre Experience.International journal of molecular sciences · 2025Article
- Differentiation of acute-phase AQP4-IgG+ optic neuritis from CNS inflammatory diseases using optic nerve head blood flow analysis.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a demyelinating disorder, distinct from multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). MOGAD most frequently presents with optic neuritis (MOG-ON), often with characteristic clinical and radiological features. Bilateral involvement, disc swelling clinically and radiologically, and longitudinally extensive optic nerve hyperintensity with associated optic perineuritis on MRI are key characteristics that can help distinguish MOG-ON from optic neuritis due to other aetiologies. The detection of serum MOG immunoglobulin G utilising a live cell-based assay in a patient with a compatible clinical phenotype is highly specific for the diagnosis of MOGAD. This review will highlight the key clinical and radiological features which expedite diagnosis, as well as ancillary investigations such as visual fields, visual evoked potentials and cerebrospinal fluid analysis, which may be less discriminatory. Optical coherence tomography can identify optic nerve swelling acutely, and atrophy chronically, and may transpire to have utility as a diagnostic and prognostic biomarker. MOG-ON appears to be largely responsive to corticosteroids, which are often the mainstay of acute management. However, relapses are common in patients in whom follow-up is prolonged, often in the context of early or rapid corticosteroid tapering. Establishing optimal acute therapy, the role of maintenance steroid-sparing immunotherapy for long-term relapse prevention, and identifying predictors of relapsing disease remain key research priorities in MOG-ON.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.